SCHEMBL12411641

SCHEMBL12411641

[C-]#[N+]c1cc2c(Oc3ccc(NC(=O)Nc4ccc(F)cc4)c(F)c3)ccnc2cc1OCC1CCCN(C)C1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.55
PDGFRA P16234 13/20 0.55
KIT P10721 2/20 0.53
FGFR2 P21802 1/20 0.53
AXL P30530 1/20 0.53
FLT1 P17948 2/20 0.50
FLT4 P35916 2/20 0.50
FGFR4 P22455 1/20 0.45
FLT3 P36888 1/20 0.45
LCK P06239 1/20 0.45
MET P08581 1/20 0.45
TEK Q02763 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12412224 0.93 KDR (0.55) KDRPDGFRAKITFGFR2AXL
SCHEMBL12412231 0.90 KDR (0.48) KDRPDGFRAKITFGFR2AXL
SCHEMBL1896415 0.89 KDR (0.56) KDRPDGFRAKITFGFR2AXL
SCHEMBL12412223 0.87 KDR (0.54) KDRPDGFRAKITFGFR2AXL
SCHEMBL12411151 0.86 KDR (0.51) KDRPDGFRAKITFGFR2AXL
SCHEMBL12411111 0.85 KDR (0.57) KDRPDGFRAKITFGFR2AXL
SCHEMBL12411133 0.85 KDR (0.57) KDRPDGFRAKITFGFR2AXL
SCHEMBL12411553 0.84 KDR (0.63) KDRPDGFRAKITFGFR2AXL
SCHEMBL12412379 0.83 FGFR4 (0.56) KDRPDGFRAKITFGFR2AXL
SCHEMBL12412087 0.82 FGFR4 (0.59) KDRPDGFRAKITFGFR2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives GNG2, GCG, FRG1 KDR 2687/4885PDGFRA 3131/4885KIT 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.